Skip to Content
 
Ingrid A.  Mayer

Ingrid A. Mayer, M.D., M.S.C.I.

Co-Leader and Clinical Director, Breast Cancer Research Program
Chair, Data and Safety Monitoring Committee
Associate Professor of Medicine (Hematology/Oncology)
Medical Oncologist

  • Appointments
    615-322-2064
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Vanderbilt Breast Center at One Hundred Oaks
    (615) 322-2064

    Office
    615-936-3831
  • Faxes
    Vanderbilt Breast Center at One Hundred Oaks Fax
    (615) 343-3343
    Office Fax
    615-343-7602
  • Addresses
    Vanderbilt Breast Center at One Hundred Oaks
    719 Thompson Lane, Suite 25000
    Nashville, TN 37204
    Website

    Office
    Vanderbilt-Ingram Cancer Center
    2220 Pierce Ave.
    777 Preston Building
    Nashville, TN 37232-6307
Profile

Dr. Mayer obtained her medical degree from the Federal University of Sáo Paulo, Brazil in 1993. Thereafter, she came to the United States for her post-graduate training (internship, residency, chief-residency and Hematology/ Oncology fellowship) at the University of Illinois at Chicago, between 1994 and 2001. During that time, Dr. Mayer received an American Society of Clinical Oncology (ASCO) Young Investigator Award in 2001 for her research project focused on the inhibitory effects of IFN-alpha in chronic myelogenous leukemia. 

In September, 2003, Dr. Mayer was recruited to Vanderbilt University as an Assistant Professor of Medicine and member of the Breast Cancer Program of the NCI-designated Vanderbilt-Ingram Cancer Center (VICC). She successfully completed a Master of Science in Clinical Investigation (MSCI) Program at Vanderbilt University in May 2006. Since then, she displayed an impressively strong commitment to a career in patient-oriented clinical and translational research in breast cancer. Her research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers. She has obtained several grants to fund her line of research, including a K23 Career Development Award, a Breast Cancer Research Foundation - American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research, and co-leadership in 3 projects in 2 of the VICC Breast Cancer Specialized Program of Research Excellence (SPORE) Grants. 

Dr. Mayer has been a Principal Investigator on more than 50 clinical trials, spanning from phase I through phase III trials. Of these, more than 10 are investigator-initiated trials (IITs), including two large Cooperative Group phase III trials through the Eastern Cooperative Oncology Group- American College of Radiology Imaging Network (ECOG-ACRIN) and a global Stand Up to Cancer (SU2C) / Translational Breast Cancer Research Consortium (TBCRC) / Novartis trial. In view of her clinical trial experience, she was appointed Chair of the Data Safety and Monitoring Committee (VICC DSMC) in 2010.

Nationally, aside from being an active member of the ECOG-ACRIN Breast Core Committee, and the VICC representative of the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Dr. Mayer has been highly involved with the Translational Breast Cancer Research Consortium (TBCRC), and since 2009, she was appointed co-Chair of the TBCRC Endocrine Resistance Working Group (ERWG). 

As a key component of the VICC Breast Cancer Program, Dr. Mayer has been the director of the Clinical Core of the VICC Breast Cancer SPORE and Clinical Team Leader of the Breast Cancer Program since 2008. In this capacity, Dr. Mayer oversees and coordinates the efforts of several physicians and full-time research support personnel, assisting with implementation and development of investigator-initiated, mechanism-based translational clinical trials, patient accrual, management, and monitoring of toxicity of patients on the trials. Under her leadership, the Breast Cancer Research Team is currently one of the top accruer of patients to VICC trials, and in 2014 she was appointed Co-Leader of the VICC Breast Cancer Program. 

Education
Doctor of Medicine
  • Federal University of Sao Paulo, Sao Paulo, Brazil
  • February, 1988 - December, 1993
Residency, Internal Medicine
  • University of Illinois at Chicago Affiliated Hospitals, Chicago, IL
  • July 1994 - June 1997
Chief Residency, Internal Medicine
  • University of Illinois at Chicago Affiliated Hospitals, Chicago, IL
  • July 1997 - June 1998
Fellowship, Hematology/OncologyUniversity of Illinois at Chicago Affiliated Hospitals, Chicago, IL
  • July 1998 - June 2001
Master of Science in Clinical Investigation
  • Vanderbilt University School of Medicine, Nashville, TN
  • September 2004 - September 2006
Research Description

Dr. Mayer research endeavors have been focused on 1) the identification of targetable pathways in breast cancer, 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers, 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers, 4) chemotherapy resistance in triple negative breast cancers, and 5) biomarker prediction of treatment response in human breast cancers.
Identification of targetable pathways in breast cancer. To enhance understanding of breast cancer biology and to elucidate molecular determinants of clinical efficacy, Dr. Mayer obtained a Vanderbilt Physician Scientist Development (VPSD) Award. The specific aims of this grant were to identify relevant tumor antigens by multidimensional liquid chromatography (LC) and tandem mass spectrometry (MS) using antibodies raised against specific peptide motifs recognized by circulating IgGs in breast cancer patients sera and to determine if these tumor antigens could be detected by immunohistochemistry in all different subsets of primary breast tumors. Preliminary results of this work led to testing of new therapeutic strategies targeting the phosphatidylinositol-3 kinase (PI3K)/Akt and correlated pathways in triple-negative, hormone-refractory and HER2-overexpressing refractory breast cancers, using biologically-based targeted agents. Initially, Dr. Mayer conducted a pilot project to determine the safety of an oral mTOR inhibitor in combination with an EGFR inhibitor in patients with metastatic breast cancer, addressing the synergism between EGFR and PI3K pathways. This study was partially funded by a Breast Cancer SPORE Pilot Project Grant. The outcome from this pilot project served as the preliminary data for her K23 Career Development Award. This grant included molecular analysis of individual breast cancers to determine how the biology of the cancer affects the response to the therapeutic agent.
ErbB signaling and endocrine therapy resistance in ER+ breast cancers. Preclinical models and some clinical observations suggest that ER+ breast cancers initially inhibited by a selective estrogen-receptor modulator (SERM) can use autocrine ErbB signaling in order to escape SERM action. This mechanism involves crosstalk between growth factor signaling and ER. Dr. Mayer obtained a Breast Cancer Research Foundation American Association for Cancer Research (BCRF-AACR) Grant for Translational Breast Cancer Research to explore if clinically combining an aromatase inhibitor with an EGFR/HER2 inhibitor would restore sensitivity to endocrine treatment in ER+/HER2+ breast cancers and would prevent the emergence of cells resistant to endocrine therapy. As a continuation of this work, funds were also obtained through the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1 to determine 1) if combined neoadjuvant breast cancer therapy with the aromatase inhibitor letrozole and the HER2 tyrosine kinase inhibitor lapatinib induces pathologic complete responses in hormone receptor-positive breast cancers that overexpress HER2 and 2) to establish biomarkers predictive of response to this therapy, 3) to determine if the post-letrozole Ki67 in hormone receptor-positive/HER2-negative tumors mirrored the recurrence score as measured by RT-PCR of 21 selected genes in formalin-fixed tumor tissue sections, and 4) to use these biomarkers to discover gene expression signatures associated with response or resistance to estrogen deprivation.
PI3K signaling and endocrine therapy resistance in ER+ breast cancers. Preclinical and a few clinical studies have already suggested that ER+/PI3K mutant tumors exhibit a lower response to antiestrogens compared to ER+/PI3K wild-type tumors. Upon recent renewal of the Breast Cancer Specialized Program of Research Excellence (SPORE), Project 1, Dr. Mayer is seeking to explore if the combination of antiestrogens with a PI3K inhibitor would be more effective against ER+/PI3K mutant

Publications
  • Mayer IA, Arteaga CL. PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer? [editorial]. J. Clin. Oncol. 2014 Sep 9/20/2014; 32(27): 2932-4. PMID: 25071103, PII: JCO.2014.55.9591, DOI: 10.1200/JCO.2014.55.9591, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25071103.
  • Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Res. Treat [print-electronic]. 2014 Jun; 145(2): 389-99. PMID: 24722917, PMCID: PMC4046906, DOI: 10.1007/s10549-014-2945-3, ISSN: 1573-7217.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24722917.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol [print-electronic]. 2014 Apr 4/20/2014; 32(12): 1202-9. PMID: 24663045, PMCID: PMC3986383, PII: JCO.2013.54.0518, DOI: 10.1200/JCO.2013.54.0518, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24663045.
  • Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Magn Reson Med [print-electronic]. 2014 Apr; 71(4): 1592-602. PMID: 23661583, PMCID: PMC3742614, DOI: 10.1002/mrm.24782, ISSN: 1522-2594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23661583.
  • Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin. Cancer Res. 2014 Feb 2/15/2014; 20(4): 782-90. PMID: 24536073, PMCID: PMC3962777, PII: 1078-0432.CCR-13-0583, DOI: 10.1158/1078-0432.CCR-13-0583, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24536073.
  • Yamaguchi NH, Mayer IA, Malzyner A, de Andrade CJ, Murad AM, Del Giglio A, Alves V. Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. J Gastrointest Oncol. 2014 Feb; 5(1): 57-66. PMID: 24490043, PMCID: PMC3904021, PII: jgo-05-01-057, DOI: 10.3978/j.issn.2078-6891.2013.056, ISSN: 2078-6891.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24490043.
  • Lenneman CG, Abdallah WM, Smith HM, Abramson V, Mayer IA, Silverstein C, Silverstein C, Means-Powell J, Paranjape SY, Lenihan D, Sawyer DB, Raj SR. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment?. Ecancermedicalscience. 2014; 8: 446. PMID: 25114718, PMCID: PMC4118731, PII: can-8-446, DOI: 10.3332/ecancer.2014.446, ISSN: 1754-6605.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25114718.
  • Mayer IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol. 2013 Nov; 11(11): 731-2. PMID: 24896546, ISSN: 1543-0790.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24896546.
  • Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer [print-electronic]. 2013 Jul 7/1/2013; 119(13): 2375-82. PMID: 23575918, PMCID: PMC3687009, DOI: 10.1002/cncr.28016, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23575918.
  • Mayer I. Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. Clin Adv Hematol Oncol. 2013 Apr; 11(4): 217-24. PMID: 23604238, PMCID: PMC3774138, ISSN: 1543-0790.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23604238.
  • Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, Mayer I, Means-Powell J, Freehardt D, White B, Lenihan D, Sawyer DB. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. J. Card. Fail. 2013 Jan; 19(1): 10-5. PMID: 23273589, PMCID: PMC3562720, PII: S1071-9164(12)01361-9, DOI: 10.1016/j.cardfail.2012.11.006, ISSN: 1532-8414.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23273589.
  • Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med. Oncol [print-electronic]. 2013; 30(2): 568. PMID: 23564368, PMCID: PMC3774143, DOI: 10.1007/s12032-013-0568-x, ISSN: 1559-131X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23564368.
  • Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Mol. Cancer Ther [print-electronic]. 2012 Oct; 11(10): 2301-5. PMID: 22879364, PMCID: PMC3682668, PII: 1535-7163.MCT-12-0511, DOI: 10.1158/1535-7163.MCT-12-0511, ISSN: 1538-8514.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22879364.
  • Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med [print-electronic]. 2012 Jul; 68(1): 261-71. PMID: 22127821, PMCID: PMC3291742, DOI: 10.1002/mrm.23205, ISSN: 1522-2594.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22127821.
  • Abramson VG, Mayer IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol. 2012 May; 4(3): 139-47. PMID: 22590487, PMCID: PMC3349077, PII: 10.1177_1758834012440834, DOI: 10.1177/1758834012440834, ISSN: 1758-8359.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22590487.
  • Li X, Abramson RG, Arlinghaus LR, Chakravarthy AB, Abramson V, Mayer I, Farley J, Delbeke D, Yankeelov TE. An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. EJNMMI Res. 2012; 2(1): 62. PMID: 23157877, PMCID: PMC3520720, PII: 2191-219X-2-62, DOI: 10.1186/2191-219X-2-62, ISSN: 2191-219X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23157877.
  • Abramson VG, Mayer IA. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol. 2011 Dec; 12(4): 403-11. PMID: 21918859, DOI: 10.1007/s11864-011-0164-2, ISSN: 1534-6277.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21918859.
  • Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Phys Med Biol [print-electronic]. 2011 Sep 9/7/2011; 56(17): 5753-69. PMID: 21841212, PMCID: PMC3176673, PII: S0031-9155(11)87575-5, DOI: 10.1088/0031-9155/56/17/018, ISSN: 1361-6560.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21841212.
  • Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE. Motion correction in diffusion-weighted MRI of the breast at 3T. J Magn Reson Imaging. 2011 May; 33(5): 1063-70. PMID: 21509862, PMCID: PMC3081111, DOI: 10.1002/jmri.22562, ISSN: 1522-2586.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21509862.
  • Mayer IA, Arteaga CL. Does lapatinib work against HER2-negative breast cancers?. Clin. Cancer Res [print-electronic]. 2010 Mar 3/1/2010; 16(5): 1355-7. PMID: 20179241, PMCID: PMC3448974, PII: 1078-0432.CCR-09-3223, DOI: 10.1158/1078-0432.CCR-09-3223, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20179241.
  • Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res [print-electronic]. 2010 Jan 1/15/2010; 16(2): 681-90. PMID: 20068102, PMCID: PMC2892225, PII: 1078-0432.CCR-09-1091, DOI: 10.1158/1078-0432.CCR-09-1091, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20068102.
  • Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res. 2009 Dec 12/15/2009; 15(24): 7479-91. PMID: 20008848, PMCID: PMC3471537, PII: 15/24/7479, DOI: 10.1158/1078-0432.CCR-09-0636, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20008848.
  • Li X, Dawant BM, Welch EB, Chakravarthy AB, Freehardt D, Mayer I, Kelley M, Meszoely I, Gore JC, Yankeelov TE. A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. Magn Reson Imaging [print-electronic]. 2009 Nov; 27(9): 1258-70. PMID: 19525078, PMCID: PMC2763059, PII: S0730-725X(09)00086-1, DOI: 10.1016/j.mri.2009.05.007, ISSN: 1873-5894.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19525078.
  • Planey CR, Welch EB, Xu L, Chakravarthy AB, Gatenby JC, Freehardt D, Mayer I, Meszeoly I, Kelley M, Means-Powell J, Gore JC, Yankeelov TE. Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer. J Magn Reson Imaging. 2009 Jul; 30(1): 121-34. PMID: 19557727, PMCID: PMC2782711, DOI: 10.1002/jmri.21812, ISSN: 1053-1807.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19557727.
  • Mayer IA. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin. Breast Cancer. 2009 Jun; 9 Suppl 2: S50-7. PMID: 19596643, PMCID: PMC3457066, PII: 7814858263518816, DOI: 10.3816/CBC.2009.s.005, ISSN: 1938-0666.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19596643.
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC, . Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2): 122-92. PMID: 19200416.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19200416.
  • Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA.. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, TX. 2009; abstract 3093.
  • Mayer IA, Means-Powell J, Shyr Y, Arteaga CL. A phase Ib trial of Erlotinib, and EGFR inhibitor, and Everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. 32nd Annual San Antonio Breast Symposium, San Antonio, TX. 2009; abstract 3094.
  • Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol [print-electronic]. 2008 Feb 2/20/2008; 26(6): 897-906. PMID: 18180460, PII: JCO.2007.13.5939, DOI: 10.1200/JCO.2007.13.5939, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18180460.
  • Guix M, Mayer IA, Meszoely IM, Arteaga CL. Evaluation of biological agents targeted at early-stage disease. Breast Cancer Res [print-electronic]. 2008; 10 Suppl 4: S25. PMID: 19128439, PMCID: PMC2614851, PII: bcr2185, DOI: 10.1186/bcr2185, ISSN: 1465-542X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19128439.
  • Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging [print-electronic]. 2007 Jan; 25(1): 1-13. PMID: 17222711, PMCID: PMC2634832, PII: S0730-725X(06)00289-X, DOI: 10.1016/j.mri.2006.09.006, ISSN: 0730-725X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17222711.
  • Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol JA. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin. Cancer Res. 2006 Mar 3/1/2006; 12(5): 1570-6. PMID: 16533783, PII: 12/5/1570, DOI: 10.1158/1078-0432.CCR-05-2304, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16533783.
  • Mayer IA. Cytokines and Cancer. [place unknown: publisher unknown]; 2005. (chapter 10).
  • Mayer IA. Targeting cytokine receptors and pathways in the treatment of breast cancer. Cancer Treat. Res. 2005; 126: 243-62. PMID: 16209069, ISSN: 0927-3042.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/16209069.
  • Rouch D, Mayer I, Truica C. Barriers to chemoprevention of breast cancer with tamoxifen. American Society of Clinical Oncology Proceedings. 2005; 41th Annual Meeting: abst 1010.
  • Chakravarthy B, Kelley M, McLaren B, Truica C, Mayer I, Brown C, Johnson K, Simpson J, Billheimer D, Pietenpol JA. Developing markers of therapeutic response using serial core biopsies to paclitaxel/radiation in stage II/III breast cancer. Breast Cancer Research and Treatment. 2004; supplement 1 (San Antonio Breast Cancer Symposium ¿ 27th Annual Meeting - Special Issue)((88)): S50 (abstract 1028).
    Available from: http://www.abstracts2view.com/sabcs/search.php?search=%5C%22do%5C%22&query%5B%5D=Chakravarthy&where%5B%5D=authors&andornot%5B%5D=and&query%5B%5D=&where%5B%5D=&andornot%5B%5D=and&query%5B%5D=&where%5B%5D=&intMaxHits=10&strt=11.
  • Costa FP, Schemerling R, Costa OF, Costa PA, Albertotti C, Martins S, Buzaid AC, Maluf F, Mayer I, Marques R. Intra-hepatic lipiodol I-131 combined with oxaliplatin, infusional FUDR, leucovorin in hepatocarcinoma and hepatic metastasis. ASCO Proceedings. 2004; 40th Annual Meeting(()): Abstract No 4133.
    Available from: http://www.asco.org/ac/1,1003,_12-002640-00_18-0026-00_19-00420,00.asp.
  • Mayer IA. Manual de Oncologia Clínica - Hospital Sírio Libanês - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores. [place unknown: publisher unknown]; 2004. (2nd edition).
  • Mayer IA. Manual de Oncologia Clínica - Hospital Sírio Libanês - Cutait R, Buzaid AC (eds). Rio de Janeiro: Reichmann & Affonso Editores. [place unknown: publisher unknown]; 2004. (2nd edition).
  • Yamaguchi NH, Mayer IA, Malzyner A, Andrade CJC, Murad AM, Giglio AD, Cardoso H.. A pilot feasibility study of gefitinib (ZD1839) and celecoxib in metastatic GI tumors. ASCO Proceedings. 2004; 40th Annual Meeting(()): Abstract No 3086.
    Available from: http://www.asco.org/ac/1,1003,_12-002640-00_18-0026-00_19-003774,00.asp.
  • Costa FC, Marques RJ, Mayer IA, Maluf FC, Martins SC, Cutait R, Buzaid AC. Irinotecan, Oxaliplatin and Raltitrexed every two weeks in untreated metastatic colorectal cancer patients. ASCO Proceedings. 2002; 38th Annual Meeting: Abstract No 2348.
    Available from: http://www.asco.org/ac/1,1003,_12-002489-00_18-002002-00_19-002348-00_28-00RESULTPAGE,00.asp.
  • Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J. Biol. Chem [print-electronic]. 2001 Jul 7/27/2001; 276(30): 28570-7. PMID: 11353767, PII: M011685200, DOI: 10.1074/jbc.M011685200, ISSN: 0021-9258.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11353767.
  • Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br. J. Haematol. 2001 Feb; 112(2): 327-36. PMID: 11167825, PII: bjh2556, ISSN: 0007-1048.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/11167825.
  • Mayer IA, Grumbach IM, Fujita S, Uddin S, Platanias LC. Activation of the p38 Map kinase pathway mediates the growth inhibitory effects of IFN-alpha in Chronic Myelogenous Leukemia. Blood. 2000; 96((11)): Abstract No 1500.
  • Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC. The Rac1/p38 Map kinase pathway is required for IFN-alpha dependent transcriptional activation but not serine phosphorylation of STAT-proteins. J Biol Chem. 2000; 275((36)): 27634-40.
    Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10878008&dopt=Abstract.